2484772-72-5
2484772-72-5
Chemical Structure
Biological Activity: Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9+ T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Seniprutug | 99.36% | Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9+ T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nasonov EL, et al. The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA. Dokl Biochem Biophys. 2025;522(1):387-403. [Content Brief]
- [2]. Um J, et al. Mechanistic Insights from Human Studies in Axial Spondyloarthritis: A T Cell Story. Curr Rheumatol Rep. 2026;28(1):6. Published 2026 Mar 5. [Content Brief]
Keywords
